Atara Biotherapeutics (ATRA) Operating Leases (2019 - 2026)

Atara Biotherapeutics has reported Operating Leases for 8 years, with the latest figure at $9.1 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases fell 66.02% year-over-year to $9.1 million; the trailing twelve-month figure through Mar 2026 stood at $9.1 million (down 66.02% YoY), and the FY2025 full-year result was $9.3 million, down 68.75% from the prior year.
• Operating Leases for Q1 2026 stood at $9.1 million, down from $9.3 million in the prior quarter.
• The five-year high for Operating Leases was $64.0 million in Q2 2022, with the low at $9.1 million in Q1 2026.
• Historically, Operating Leases has averaged $36.7 million across 5 years, with a median of $38.7 million in 2024.
• Annual changes were most pronounced in 2022 — Operating Leases soared 425.36% — and 2025, when it tumbled 68.75%.
• Atara Biotherapeutics' Operating Leases stood at $58.1 million in 2022, then dropped by 21.31% to $45.7 million in 2023, then plunged by 34.53% to $29.9 million in 2024, then plunged by 68.75% to $9.3 million in 2025, then retreated by 2.9% to $9.1 million in 2026.
• The last three Operating Leases figures came in at $9.1 million (Q1 2026), $9.3 million (Q4 2025), and $15.0 million (Q3 2025), per Business Quant data.